**Figure 2. Olaparib sensitivity in cells transformed with the EWS-FLI1 rearrangement.** Illustrates the results of cell viability assays performed for EWS-FLI1 and FUS-CHOP transformed mouse mesenchymal cells, as well as the human Ewing’s sarcoma cell line (SK-N-MC), which harbors the EWS-FLI1 fusion. Cells were treated with olaparib and 72 hr later cell viability was determined. Relative viability was calculated as a percentage of vehicle control treated cells. Access the [full size image][1] and [R script][2] used to generate this figure. <br> **Figure 2 - figure supplement 1. Population doubling time of cells and confirmation of EWS-FLI1 rearrangement.** For each cell line, relative viability of untreated and vehicle control treated cells at 24 and 72 hr after treatment with olaparib were used to determine the population doubling times. Also, relative expression levels of EWS-FLI1 and Actb were determined by qRT-PCR for each cell line. Expression level of EWS-FLI1 transformed mouse mesenchymal cells was assigned a value of 100. Access the [full size image][3] and R scripts [here][4] and [here][5] that were used to generate this figure. [1]: https://osf.io/75d4c/ [2]: https://osf.io/m75vs/ [3]: https://osf.io/kg2vw/ [4]: https://osf.io/w68b4/ [5]: https://osf.io/dzh3j/